HRP20192013T1 - Liječenje cd47+ oboljelih stanica sa sirp alfa-fc fuzijama - Google Patents
Liječenje cd47+ oboljelih stanica sa sirp alfa-fc fuzijama Download PDFInfo
- Publication number
- HRP20192013T1 HRP20192013T1 HRP20192013TT HRP20192013T HRP20192013T1 HR P20192013 T1 HRP20192013 T1 HR P20192013T1 HR P20192013T T HRP20192013T T HR P20192013TT HR P20192013 T HRP20192013 T HR P20192013T HR P20192013 T1 HRP20192013 T1 HR P20192013T1
- Authority
- HR
- Croatia
- Prior art keywords
- fusion protein
- human sirpα
- sirpα fusion
- cell
- seq
- Prior art date
Links
- 101150036449 SIRPA gene Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000004927 fusion Effects 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 claims 26
- 102000037865 fusion proteins Human genes 0.000 claims 26
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 23
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 23
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 11
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- 230000014616 translation Effects 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Claims (20)
1. Humani SIRPα fuzijski protein koristan da inhibira rast i/ili proliferaciju CD47+ oboljele stanice, gdje humani SIRPα fuzijski protein sadrži SEQ ID No. 25.
2. Humani SIRPα fuzijski protein prema patentnom zahtjevu 1, gdje se humani SIRPα fuzijski protein sastoji od SEQ ID No. 25.
3. Humani SIRPα fuzijski protein prema patentnom zahtjevu 1 ili 2, koji dalje sadrži oznaku koja se može detektirati.
4. Farmaceutska kompozicija koja sadrži farmaceutski prihvatljiv nosač i količinu humanog SIRPα fuzijskog proteina efikasnu da inhibira rast ili proliferaciju CD47+ oboljele stanice, gdje humani SIRPα fuzijski protein sadrži SEQ ID No. 25.
5. Farmaceutska kompozicija prema patentnom zahtjevu 4, gdje se humani SIRPα fuzijski protein sastoji od SEQ ID No. 25.
6. Humani SIRPα fuzijski protein koji sadrži SEQ ID No. 25, za primjenu u inhibiranju rasta CD47+ oboljelih stanica kod subjekta koji ima potrebu za istom.
7. Humani SIRPα fuzijski protein za primjenu prema patentnom zahtjevu 6, gdje je oboljela stanica CD47+ stanica raka.
8. Humani SIRPα fuzijski protein za primjenu prema patentnom zahtjevu 6 ili 7, gdje je oboljela stanica CD47+ stanica hematološkog raka.
9. Humani SIRPα fuzijski protein za primjenu prema patentnom zahtjevu 8, gdje je oboljela stanica CD47+ stanica leukemije.
10. Humani SIRPα fuzijski protein za primjenu prema patentnom zahtjevu 7, gdje je oboljela stanica solidni tumor koji sadrži CD47+ stanice raka.
11. Humani SIRPα fuzijski protein za primjenu prema bilo kojem od patentnih zahtjeva 6-10, gdje se humani SIRPα fuzijski protein sastoji od SEQ ID No. 25.
12. DNK konstrukcija koja sadrži nukleotidnu sekvencu koja kodira humani SIRPα fuzijski protein prema patentnom zahtjevu 1 ili 2.
13. Stanica domaćina za proizvodnju proteina, koja sadrži eksprimirajuću inkorporiranu DNK konstrukciju prema patentnom zahtjevu 12.
14. Metoda za proizvodnju humanog SIRPα fuzijskog proteina, koja obuhvaća kultiviranje stanice domaćina za proizvodnju proteina koja ima, radi eksprimiranja u njoj, polinukleotid koji kodira humani SIRPαFc fuzijski protein koji sadrži ili se sastoji od SEQ ID No. 25.
15. Dimerni fuzijski protein koji sadrži dva jednolančana polipeptida fuzionirana preko njihovih odgovarajućih Fc komponenti, pri čemu je svaki jednolančani polipeptid humani SIRPα fuzijski protein iz patentnog zahtjeva 1 ili patentnog zahtjeva 2.
16. Farmaceutska kompozicija koja sadrži farmaceutski prihvatljiv nosač i količinu dimernog humanog SIRPα fuzijskog proteina prema patentnom zahtjevu 15 efikasnu da inhibira rast ili proliferaciju CD47+ oboljele stanice.
17. Dimerni humani SIRPα fuzijski protein prema patentnom zahtjevu 15, za primjenu u inhibiranju rasta CD47+ oboljelih stanica kod subjekta koji ima potrebu za istom.
18. Dimerni humani SIRPα fuzijski protein za primjenu prema patentnom zahtjevu 17, gdje je oboljela stanica CD47+ stanica raka.
19. Dimerni humani SIRPα fuzijski protein za primjenu prema patentnom zahtjevu 17, gdje je oboljela stanica CD47+ stanica hematološkog raka.
20. Metoda za proizvodnju dimernog humanog SIRPα fuzijskog proteina prema patentnom zahtjevu 15, koja obuhvaća kultiviranje stanice domaćina za proizvodnju proteina koja ima inkorporiran, radi eksprimiranja u njoj, polinukleotid koji kodira tajni oblik humanog SIRPaFc fuzijskog proteina koji sadrži ili se sastoji od SEQ ID No. 25.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261738008P | 2012-12-17 | 2012-12-17 | |
EP13865442.1A EP2931752B1 (en) | 2012-12-17 | 2013-12-17 | Treatment of cd47+ disease cells with sirp alpha-fc fusions |
PCT/CA2013/001046 WO2014094122A1 (en) | 2012-12-17 | 2013-12-17 | Treatment of cd47+ disease cells with sirp alpha-fc fusions |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20192013T1 true HRP20192013T1 (hr) | 2020-02-07 |
Family
ID=50977456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20192013TT HRP20192013T1 (hr) | 2012-12-17 | 2019-11-07 | Liječenje cd47+ oboljelih stanica sa sirp alfa-fc fuzijama |
Country Status (19)
Country | Link |
---|---|
US (3) | US9969789B2 (hr) |
EP (3) | EP2931752B1 (hr) |
JP (3) | JP6335189B2 (hr) |
CN (2) | CN105073780B (hr) |
AU (4) | AU2013362789B8 (hr) |
CA (2) | CA3145468A1 (hr) |
CY (1) | CY1122463T1 (hr) |
DK (2) | DK2931752T3 (hr) |
ES (2) | ES2914814T3 (hr) |
HK (1) | HK1217716A1 (hr) |
HR (1) | HRP20192013T1 (hr) |
HU (2) | HUE058790T2 (hr) |
LT (1) | LT2931752T (hr) |
ME (1) | ME03550B (hr) |
PL (2) | PL2931752T3 (hr) |
PT (2) | PT3575326T (hr) |
RS (1) | RS59591B1 (hr) |
SI (2) | SI3575326T1 (hr) |
WO (1) | WO2014094122A1 (hr) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI2995315T3 (fi) | 2009-05-15 | 2024-03-18 | Univ Health Network | Koostumuksia ja menetelmiä hematologisten syöpien hoitamiseksi kohdistuen sirp-alfan ja cd47:n interaktioon |
HUE058790T2 (hu) * | 2012-12-17 | 2022-09-28 | Pf Argentum Ip Holdings Llc | CD47+ beteg sejtek kezelése SIRP-alfa-Fc fúziókkal |
GB2532619A (en) * | 2014-08-08 | 2016-05-25 | Alexo Therapeutics Int | Sirp-Alpha Variant Constructs And Uses Thereof |
WO2016023001A1 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
EP3177640B1 (en) | 2014-08-08 | 2020-05-06 | The Board of Trustees of the Leland Stanford Junior University | High affinity pd-1 agents and methods of use |
EP3643727A1 (en) | 2014-08-15 | 2020-04-29 | Merck Patent GmbH | Sirp-alpha immunoglobulin fusion proteins |
CN106146670B (zh) * | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术(上海)有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
BR102016018074A2 (pt) * | 2015-08-07 | 2021-11-16 | ALX Oncology Inc. | Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica |
PT3331902T (pt) | 2015-08-07 | 2021-07-26 | Alx Oncology Inc | Construções com um domínio de sirp-alfa ou uma sua variante |
BR112018006578A2 (pt) | 2015-10-01 | 2018-12-26 | Heat Biologics, Inc. | composições e métodos para juntar domínios extracelulares tipo i e tipo ii como proteínas quiméricas heterólogas |
KR20220163516A (ko) | 2016-01-11 | 2022-12-09 | 포티 세븐, 인코포레이티드 | 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체 |
CN107149682B (zh) * | 2016-03-04 | 2022-01-04 | 复旦大学 | 一种靶向cd47的免疫检查点抑制剂药物组合物及其制备方法 |
EP3442593A4 (en) * | 2016-04-15 | 2020-01-01 | Trillium Therapeutics Inc. | STIMULATION OF MACROPHAGES IN THERAPY BY CD47 BLOCKING |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
US11560433B2 (en) | 2016-05-27 | 2023-01-24 | Albert Einstein College Of Medicine | Methods of treatment by targeting VCAM1 and MAEA |
CN107459578B (zh) * | 2016-05-31 | 2021-11-26 | 泰州迈博太科药业有限公司 | 一种靶向cd47与pd-l1的双功能融合蛋白 |
CN107459579B (zh) * | 2016-06-01 | 2021-09-24 | 泰州迈博太科药业有限公司 | 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用 |
WO2018012952A1 (ko) * | 2016-07-15 | 2018-01-18 | 한국과학기술연구원 | 신규 나노케이지 및 그의 용도 |
CA3030926A1 (en) * | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd47 combination therapy |
JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
WO2018081448A1 (en) | 2016-10-26 | 2018-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
WO2018081898A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
EP3534964A4 (en) * | 2016-11-03 | 2020-07-15 | Trillium Therapeutics Inc. | IMPROVEMENT OF CD47 BLOCKING THERAPY BY PROTEASOME INHIBITORS |
EP3563835A4 (en) | 2016-12-29 | 2020-12-30 | Korea Institute of Science and Technology | NEW EXOSOME-BASED ANTI-CANCER AGENT |
CN108277234A (zh) * | 2017-01-05 | 2018-07-13 | 上海白泽生物科技有限公司 | 封闭cd47并激发抗肿瘤免疫的重组溶瘤腺病毒及其用途 |
GB201700567D0 (en) | 2017-01-12 | 2017-03-01 | Genagon Therapeutics Ab | Therapeutic agents |
US11384154B2 (en) | 2017-02-06 | 2022-07-12 | Orionis Biosciences BV | Targeted chimeric proteins and uses thereof |
WO2018157163A1 (en) | 2017-02-27 | 2018-08-30 | Shattuck Labs, Inc. | Vsig8-based chimeric proteins |
BR112019017713A2 (pt) | 2017-02-27 | 2020-04-07 | Shattuck Labs Inc | proteínas quiméricas à base de csf1r |
US11332509B2 (en) | 2017-02-27 | 2022-05-17 | Shattuck Labs, Inc. | Methods of making and using extracellular domain-based chimeric proteins |
US20200157179A1 (en) * | 2017-03-28 | 2020-05-21 | Trillium Therapeutics Inc. | Cd47 blockade therapy |
CN108864290B (zh) * | 2017-05-08 | 2021-12-07 | 上海津曼特生物科技有限公司 | 双特异性重组蛋白及其应用 |
CN113896792A (zh) | 2017-05-12 | 2022-01-07 | 哈普恩治疗公司 | 间皮素结合蛋白质 |
WO2019027903A1 (en) | 2017-08-02 | 2019-02-07 | Phanes Therapeutics, Inc. | ANTI-CD47 ANTIBODIES AND USES THEREOF |
CN109422811A (zh) * | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
KR20190037164A (ko) * | 2017-09-28 | 2019-04-05 | 한국과학기술연구원 | 신규 암 치료용 조성물 |
MX2020003856A (es) | 2017-10-13 | 2020-08-13 | Harpoon Therapeutics Inc | Proteinas de union a antigenos de maduracion de celulas b. |
EP3706775A4 (en) | 2017-11-06 | 2021-09-01 | Trillium Therapeutics Inc. | BLOCKING OF CD47 ASSOCIATED WITH RADIATION THERAPY |
BR112020010020A2 (pt) * | 2017-11-20 | 2020-11-10 | Taizhou Mabtech Pharmaceutical Co., Ltd | uma proteína de fusão bifuncional direcionada a cd47 e pd-l1 |
CA3090489A1 (en) | 2018-02-12 | 2019-08-15 | Forty Seven, Inc. | Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies |
CN108484774B (zh) * | 2018-03-09 | 2021-11-05 | 上海高菲生物科技有限公司 | 一种SIRPα融合蛋白及其制备方法和用途 |
US20210040224A1 (en) * | 2018-03-13 | 2021-02-11 | Trillium Therapeutics Inc. | Cd47 blockade therapy with cd38 antibody |
WO2019173903A1 (en) * | 2018-03-13 | 2019-09-19 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by egfr antibody |
JP7393342B2 (ja) | 2018-03-21 | 2023-12-06 | エーエルエックス オンコロジー インコーポレイテッド | シグナル調節タンパク質αに対する抗体及び使用方法 |
CN110305212A (zh) | 2018-03-27 | 2019-10-08 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
CN110386984B (zh) | 2018-04-17 | 2022-04-22 | 杭州尚健生物技术有限公司 | 结合cd47蛋白的融合蛋白及其应用 |
CN108794641A (zh) * | 2018-07-04 | 2018-11-13 | 上海科医联创生物科技有限公司 | 一种针对EGFRvIII的多功能融合蛋白及其应用 |
EP3822289A4 (en) | 2018-07-10 | 2022-04-13 | National University Corporation Kobe University | ANTIBODY ANTI-SIRP ALPHA |
US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
MA53493A (fr) | 2018-08-31 | 2021-07-07 | Alx Oncology Inc | Polypeptides leurres |
WO2020047651A1 (en) | 2018-09-04 | 2020-03-12 | Trillium Therapeutics Inc. | Cd47 blockade with parp inhibition for disease treatment |
CA3114038A1 (en) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
EP3880215A4 (en) * | 2018-11-13 | 2023-02-15 | Memorial Sloan Kettering Cancer Center | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER |
CN109517054B (zh) * | 2018-12-04 | 2022-04-08 | 江苏东抗生物医药科技有限公司 | SIRPα变体或其融合蛋白及其应用 |
CA3132078A1 (en) | 2019-03-06 | 2020-09-10 | Jiangsu Hengrui Medicine Co., Ltd. | Bifunctional fusion protein and pharmaceutical use thereof |
AU2020282791A1 (en) | 2019-05-31 | 2021-12-09 | ALX Oncology Inc. | Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor |
MA56119A (fr) | 2019-06-07 | 2022-04-13 | Alx Oncology Inc | Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
EP4045083B1 (en) | 2019-10-18 | 2024-01-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
IL293199A (en) | 2019-11-27 | 2022-07-01 | Alx Oncology Inc | Combined therapies for cancer treatment |
CN111253482B (zh) * | 2020-02-18 | 2021-11-30 | 中国人民解放军军事科学院军事医学研究院 | SIRPa变体、融合蛋白、及其应用 |
EP4157315A1 (en) | 2020-06-01 | 2023-04-05 | ALX Oncology Inc. | Combination therapies comprising a hypomethylation agent for treating cancer |
WO2022010806A1 (en) | 2020-07-06 | 2022-01-13 | ALX Oncology Inc. | Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays |
CA3182579A1 (en) | 2020-07-07 | 2022-01-13 | Ugur Sahin | Therapeutic rna for hpv-positive cancer |
CN114057888A (zh) * | 2020-07-30 | 2022-02-18 | 三生国健药业(上海)股份有限公司 | 一种SIRPα-Fc融合蛋白 |
EP4232052A1 (en) * | 2020-10-22 | 2023-08-30 | Actinium Pharmaceuticals, Inc. | Combination radioimmunotherapy and cd47 blockade in the treatment of cancer |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
WO2022120286A1 (en) | 2020-12-06 | 2022-06-09 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
EP4262828A1 (en) | 2020-12-18 | 2023-10-25 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
JP2024515211A (ja) | 2021-04-27 | 2024-04-05 | ファイザー・インク | Dhfr阻害剤を用いたcd47遮断療法の増強 |
AU2022273727A1 (en) | 2021-05-13 | 2023-11-09 | ALX Oncology Inc. | Combination therapies for treating cancer |
AU2022312698A1 (en) | 2021-07-13 | 2024-01-25 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
WO2023006390A1 (en) * | 2021-07-30 | 2023-02-02 | Ludwig-Maximilians-Universität München | Mesothelin antibodies and use thereof |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
WO2023073580A1 (en) | 2021-10-29 | 2023-05-04 | Pfizer Inc. | Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy |
WO2023079438A1 (en) | 2021-11-08 | 2023-05-11 | Pfizer Inc. | Enhancement of cd47 blockade therapy with anti-vegf agents |
EP4340893A1 (en) | 2021-11-19 | 2024-03-27 | KIST (Korea Institute of Science and Technology) | Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell |
US20230203202A1 (en) | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
US20230220106A1 (en) | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
WO2023121887A2 (en) * | 2021-12-21 | 2023-06-29 | Fbd Biologics Limited | ENGINEERED SIRPα VARIANTS AND METHODS OF USE THEREOF |
WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
WO2023183890A1 (en) | 2022-03-24 | 2023-09-28 | Bitterroot Bio, Inc. | Multivalent sirp-alpha fusion polypeptides |
WO2023183892A1 (en) | 2022-03-24 | 2023-09-28 | Bitterroot Bio, Inc. | Sirp-alpha fusion polypeptides with modified fc domains |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TW202400650A (zh) | 2022-05-11 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體與cd47抑制劑之組合 |
WO2023228044A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Dosing regimens of sirp alpha fusion proteins for treatment of cancer |
US20240010701A1 (en) | 2022-06-01 | 2024-01-11 | ALX Oncology Inc. | Combination therapies for treating urothelial carcinoma |
WO2024025264A1 (en) * | 2022-07-24 | 2024-02-01 | Shiftbio Co., Ltd. | Method for treating cancer and inflammatory diseases using stem cell- derived extracellular vesicles comprising sirp |
WO2024040151A1 (en) | 2022-08-18 | 2024-02-22 | Pfizer Inc. | Sirp alpha fusion protein and anti-cd38 antibody combination therapies |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US6641809B1 (en) | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
WO1997048723A2 (en) | 1996-06-17 | 1997-12-24 | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. Hofgartenstrasse 2 | Ptp-20, pcp-2, bdp1, clk and sirp proteins and related products |
US7074589B1 (en) * | 1996-06-17 | 2006-07-11 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Nucleic acids encoding BDP-1 |
US6541615B1 (en) | 1996-11-15 | 2003-04-01 | Max-Planck-Gellschaft Zur Foderung Der Wissenschaften E.V. | SIRP proteins and uses thereof |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
CA2226962A1 (en) | 1998-02-16 | 1999-08-16 | Marie Sarfati | Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection |
EP1048299A1 (en) | 1999-04-28 | 2000-11-02 | Faculteit der Geneeskunde van de Vrije Universiteit | Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies |
AU1701001A (en) | 1999-11-30 | 2001-06-12 | Eberhard-Karls-Universitat Tubingen Universitatsklinikum | Antibodies against signal regulator proteins |
GB9930706D0 (en) | 1999-12-24 | 2000-02-16 | Medical Res Council | Composition for inhibiting macrophage activity |
US7282556B2 (en) | 2001-05-15 | 2007-10-16 | Emory University | Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47 |
US6541516B1 (en) | 2001-09-14 | 2003-04-01 | Isp Investments Inc. | Water miscible emulsions of pyrethroid insecticides or triazole fungicides |
EP1369128A1 (en) | 2002-06-07 | 2003-12-10 | Procorde GmbH | Inhibitors of glycoprotein VI and their therapeutic use |
ATE541857T1 (de) * | 2002-09-27 | 2012-02-15 | Xencor Inc | Optimierte fc-varianten und herstellungsverfahren dafür |
US20040213792A1 (en) | 2003-04-24 | 2004-10-28 | Clemmons David R. | Method for inhibiting cellular activation by insulin-like growth factor-1 |
JP3936673B2 (ja) | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Cd47部分ペプチドと抗shps−1モノクロナール抗体 |
US8101719B2 (en) | 2003-11-11 | 2012-01-24 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-CD47 antibody |
EP1855724A2 (en) * | 2005-02-01 | 2007-11-21 | Research Development Foundation | Blys fusion proteins for targeting blys receptor and methods for treatment of b-cell proliferative disorders |
WO2007014123A2 (en) | 2005-07-22 | 2007-02-01 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
US7514229B2 (en) | 2005-09-29 | 2009-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and evaluating treatment of blood disorders |
EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
AU2007213709A1 (en) | 2006-02-08 | 2007-08-16 | Targeted Molecular Diagnostics, Llc | Bivalent ErbB ligand binding molecules and methods for their preparation and use |
US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
EP2027151A2 (en) | 2006-05-15 | 2009-02-25 | Viral Logic Systems Technology Corp. | Cd47 related compositions and methods for treating immunological diseases and disorders |
JP5189082B2 (ja) * | 2006-05-25 | 2013-04-24 | バイエル・ファルマ・アクチェンゲゼルシャフト | 二量体分子複合体 |
CN103242444A (zh) * | 2007-10-11 | 2013-08-14 | 大学健康网络 | 调节SIRPα-CD47相互作用以增加造血干细胞植入和用于此的化合物 |
US8541543B2 (en) * | 2007-11-20 | 2013-09-24 | Academia Sinica | Peptides specific for hepatocellular carcinoma cells and applications thereof |
DE102007056623B3 (de) | 2007-11-23 | 2009-05-20 | Mtu Friedrichshafen Gmbh | Verfahren zur Regelung eines stationären Gasmotors |
EP4160212B1 (en) | 2008-01-15 | 2024-04-17 | The Board of Trustees of the Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
CA2711938C (en) | 2008-01-15 | 2019-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for manipulating phagocytosis mediated by cd47 |
EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
JP2012512640A (ja) | 2008-12-19 | 2012-06-07 | ノバルティス アーゲー | 自己免疫および炎症性障害の処置に使用するための可溶性ポリペプチド |
WO2010083253A2 (en) | 2009-01-14 | 2010-07-22 | Viral Logic Systems Technology Corp. | Cd47 related compositions and methods for treating immunological diseases and disorders |
FI2995315T3 (fi) * | 2009-05-15 | 2024-03-18 | Univ Health Network | Koostumuksia ja menetelmiä hematologisten syöpien hoitamiseksi kohdistuen sirp-alfan ja cd47:n interaktioon |
KR20120107122A (ko) | 2009-12-22 | 2012-09-28 | 노파르티스 아게 | 치료법에서 사용하기 위한 4가 cd47―항체 불변 영역 융합 단백질 |
DK2569013T3 (da) | 2010-05-14 | 2017-02-13 | Univ Leland Stanford Junior | Humaniserede og kimære monoklonale antistoffer til cd47 |
JP6147670B2 (ja) | 2010-12-22 | 2017-06-14 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 改善された半減期を有する修飾された抗体 |
US20140242095A1 (en) | 2011-10-19 | 2014-08-28 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
DK2804617T3 (da) * | 2012-01-17 | 2020-08-10 | Univ Leland Stanford Junior | Højaffine sirp-alpha-reagenser |
PL2812443T3 (pl) | 2012-02-06 | 2020-01-31 | Inhibrx, Inc. | Przeciwciała CD47 i sposoby ich zastosowania |
EP2931751B1 (en) | 2012-12-12 | 2020-02-05 | Arch Oncology, Inc. | Therapeutic cd47 antibodies |
HUE058790T2 (hu) | 2012-12-17 | 2022-09-28 | Pf Argentum Ip Holdings Llc | CD47+ beteg sejtek kezelése SIRP-alfa-Fc fúziókkal |
JP2016507555A (ja) | 2013-02-06 | 2016-03-10 | インヒブルクス エルピー | 血小板非減少性かつ赤血球非減少性cd47抗体及びその使用方法 |
GB2532619A (en) | 2014-08-08 | 2016-05-25 | Alexo Therapeutics Int | Sirp-Alpha Variant Constructs And Uses Thereof |
EP4321171A3 (en) | 2014-08-08 | 2024-05-15 | The Board of Trustees of the Leland Stanford Junior University | Sirp alpha-antibody fusion proteins |
EP3643727A1 (en) | 2014-08-15 | 2020-04-29 | Merck Patent GmbH | Sirp-alpha immunoglobulin fusion proteins |
EP3442593A4 (en) | 2016-04-15 | 2020-01-01 | Trillium Therapeutics Inc. | STIMULATION OF MACROPHAGES IN THERAPY BY CD47 BLOCKING |
US20200157179A1 (en) | 2017-03-28 | 2020-05-21 | Trillium Therapeutics Inc. | Cd47 blockade therapy |
-
2013
- 2013-12-17 HU HUE19185175A patent/HUE058790T2/hu unknown
- 2013-12-17 LT LT13865442T patent/LT2931752T/lt unknown
- 2013-12-17 CN CN201380073010.1A patent/CN105073780B/zh active Active
- 2013-12-17 CN CN201910261473.XA patent/CN110066341B/zh active Active
- 2013-12-17 US US14/653,165 patent/US9969789B2/en active Active
- 2013-12-17 AU AU2013362789A patent/AU2013362789B8/en active Active
- 2013-12-17 ME MEP-2019-310A patent/ME03550B/me unknown
- 2013-12-17 EP EP13865442.1A patent/EP2931752B1/en active Active
- 2013-12-17 ES ES19185175T patent/ES2914814T3/es active Active
- 2013-12-17 EP EP22162692.2A patent/EP4116331A1/en active Pending
- 2013-12-17 WO PCT/CA2013/001046 patent/WO2014094122A1/en active Application Filing
- 2013-12-17 JP JP2015548121A patent/JP6335189B2/ja active Active
- 2013-12-17 CA CA3145468A patent/CA3145468A1/en active Pending
- 2013-12-17 SI SI201331996T patent/SI3575326T1/sl unknown
- 2013-12-17 ES ES13865442T patent/ES2755156T3/es active Active
- 2013-12-17 DK DK13865442T patent/DK2931752T3/da active
- 2013-12-17 PL PL13865442T patent/PL2931752T3/pl unknown
- 2013-12-17 SI SI201331610T patent/SI2931752T1/sl unknown
- 2013-12-17 DK DK19185175.7T patent/DK3575326T3/da active
- 2013-12-17 EP EP19185175.7A patent/EP3575326B8/en active Active
- 2013-12-17 PT PT191851757T patent/PT3575326T/pt unknown
- 2013-12-17 RS RS20191446A patent/RS59591B1/sr unknown
- 2013-12-17 PT PT138654421T patent/PT2931752T/pt unknown
- 2013-12-17 CA CA2894245A patent/CA2894245C/en active Active
- 2013-12-17 HU HUE13865442A patent/HUE047221T2/hu unknown
- 2013-12-17 PL PL19185175T patent/PL3575326T3/pl unknown
-
2016
- 2016-05-18 HK HK16105678.0A patent/HK1217716A1/zh unknown
-
2018
- 2018-02-13 AU AU2018201039A patent/AU2018201039A1/en not_active Abandoned
- 2018-04-25 US US15/962,540 patent/US10906954B2/en active Active
- 2018-04-26 JP JP2018084885A patent/JP6664430B2/ja active Active
-
2019
- 2019-11-07 HR HRP20192013TT patent/HRP20192013T1/hr unknown
- 2019-11-13 CY CY20191101192T patent/CY1122463T1/el unknown
-
2020
- 2020-02-17 JP JP2020023936A patent/JP7149450B2/ja active Active
- 2020-03-25 AU AU2020202119A patent/AU2020202119B2/en active Active
- 2020-12-23 US US17/133,489 patent/US20210206829A1/en active Pending
-
2022
- 2022-11-25 AU AU2022275518A patent/AU2022275518A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20192013T1 (hr) | Liječenje cd47+ oboljelih stanica sa sirp alfa-fc fuzijama | |
HRP20211594T1 (hr) | Anti-pd1 protutijela i načini uporabe | |
SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
BR112019005587A2 (pt) | proteínas de ligação recombinantes e sua utilização | |
MX2017014716A (es) | Polipeptido de fusion anti-cancer. | |
HRP20220147T1 (hr) | Pripravci i postupci povezani s multimodalnim terapijskim staničnim sustavima za indikacije raka | |
MX2013002379A (es) | Moleculas de union a vegf. | |
EA201890456A1 (ru) | Новый слитый полипептид, специфичный в отношении lag-3 и pd-1 | |
MY189425A (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use | |
AR090047A1 (es) | Dominio variable dual de inmunoglobulinas y sus usos | |
MX2021010416A (es) | Moleculas fc biespecificas. | |
AR082017A1 (es) | Anticuerpos anti-axl (receptor de tirosina quinasas) y metodos de uso | |
MX2020006065A (es) | Metodos y productos para la produccion y administracion de acido nucleico. | |
PH12020550240A1 (en) | D-domain containing polypeptides and uses thereof | |
MY193497A (en) | Anti-myostatin antibodies and methods of use | |
MX352265B (es) | Neurotoxinas que exhiben actividad biologica acortada. | |
TN2012000144A1 (en) | Dll4-binding molecules | |
CL2011002756A1 (es) | Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad. | |
MX2017009153A (es) | Proteinas de fusion de citoquinas. | |
EA201400964A1 (ru) | Cx3cr1-связывающие полипептиды | |
NZ711567A (en) | Antibody formulations | |
CO6680702A2 (es) | Péptido o complejo péptido que se une a integrina alfa 2 y metodos y sus usos que implican a los mismos | |
EA201501080A1 (ru) | Новое применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения различных заболеваний | |
IL196673A (en) | A protein displaying biological activities similar to those of human interferon, an isolated polynucleotide encoding it, a recombinant vector containing this isolated polynucleotide and a storage cell containing this recombinant vector | |
MX366178B (es) | Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. |